TORONTO, CANADA–(Marketwired – Sept. 17, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced AB569, the Company’s drug candidate for treating pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections, has successfully completed pre-clinical in vivo and in vitro validation studies.
Press Releases
Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Targeting Peptides
TORONTO, CANADA–(Marketwired – Aug. 5, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,095,541 titled, “Brain Tumor Targeting Peptides”, further protecting MetaMx™, the Company’s peptide based technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).
Arch Biopartners Announces Issuance of a Second U.S. Patent for Peptide Solid Surface Interface
TORONTO, ONTARIO–(Marketwired – Aug. 4, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 9,096,775 titled, “Surface Coated Structures and Methods”.
Arch Scientists Use ‘BORG’ Peptides to Improve Biocompatibilty of Polysulfone for Use in Dialysis
TORONTO, ONTARIO–(Marketwired – July 23, 2015) – Arch Biopartners Inc (Arch) or (the Company)(TSX VENTURE:ACH) (OTCBB:FOIFF) announced today that Arch scientists have published details of their new technology and its potential applications in the area of dialysis.
Dr. Sheila Singh, MD PhD. Joins Arch Biopartners as Medical and Clincial Advisor
TORONTO, ONTARIO–(Marketwired – June 8, 2015) – Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced Dr. Sheila Singh will join the Company as a medical and clinical advisor to the development of MetaMx™, the Company’s brain tumor initiating cell (BTIC) targeting technology.
Arch Biopartners 2015 AGM Results and Technology Status Update
TORONTO, CANADA–(Marketwired – April 1, 2015) – Arch Biopartners Inc (“Arch”) or the “Company”)(TSX VENTURE:ACH) and (OTCBB:FOIFF) announced results from its Annual General Meeting of Shareholders held in Toronto on March 30, 2015.
Arch Biopartners Identifies Candidate Drug to Treat Psuedomonas Respiratory Infections
TORONTO, ONTARIO–(Marketwired – March 18, 2015) – Arch Biopartners Inc (“Arch”) or the “Company”)(TSX VENTURE:ACH) and (OTCBB:FOIFF) announced today it has identified a new candidate drug to treat Pseudomonas aeruginosa respiratory infections.
Arch Biopartners Announces Issuance of U.S. Patent for Peptide Solid Surface Interface
TORONTO, ONTARIO–(Marketwired – Feb. 25, 2015) – Arch Biopartners Inc (“Arch” or the “Company”) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today the U.S. Patent and Trademark Office has issued U.S. Patent 8,961,984, titled “Surface Coated Structures and Methods” protecting its peptide-solid surface technology which has been shown to reduce biofilm formation, corrosion and friction on various metals and plastics.
Arch Biopartners Receives Final Approval to List on TSX Venture Exchange
TORONTO, ONTARIO–(Marketwired – Feb. 19, 2015) – Arch Biopartners Inc (“Arch” or the “Company”) (CSE:ACH)(OTCBB:FOIFF) has received final approval for its common shares to be listed on the TSX Venture Exchange (TSXV).
Arch Biopartners Completes Private Placement
TORONTO, ONTARIO–(Marketwired – Jan. 26, 2015) – Arch Biopartners Inc (“Arch or the “Company”) (CSE:ACH)(OTCBB:FOIFF) announced today it has raised an additional $90,650 by closing the second tranche of the non-brokered private placement it announced in a press release January 6, 2015.